CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Centogene Extends Collaboration with Takeda

Life Sciences Review Life Sciences Review | Thursday, May 27, 2021
Tweet

Centogene recently reported that it had expanded its collaboration with Takeda Pharmaceutical Company Limited to detect patients with specific genetic disorders.


FREMONT, CA: Centogene N.V., a commercial-stage organization prioritizing rare diseases that turns real-world clinical and genetic data into actionable insights for patients, doctors, and pharmaceutical companies, recently reported that it has extended its collaboration with Takeda Pharmaceutical Company Limited to detect patients with specific genetic disorders.


CENTOGENE will continue to provide genetic testing to patients worldwide as part of the deal, which has been renewed until March 2022.


Andrin Oswald, M.D., CEO of CENTOGENE, said, "We are pleased to be extending our partnership with Takeda, which will allow us to continue diagnosing and connecting rare disease patients globally. There is still a lot of work to be done, but with each step, we are closer to bringing patients the life-saving medical solutions they need."


In January 2015, CENTOGENE signed an agreement with Shire Pharmaceuticals, a Takeda Pharmaceutical Company Limited subsidiary, to offer diagnostic testing abilities to improve the early diagnosis of patients with rare genetic diseases.


CENTOGENE specializes in rare disease diagnosis and research, converting real-world clinical and genetic data into actionable insights for patients, doctors, and pharmaceutical firms. Their mission is to use comprehensive rare disease knowledge, including epidemiological and clinical data and advanced biomarkers, to add rationality to treatment decisions and accelerate the production of new orphan drugs. As of September 30, 2020, CENTOGENE has created a global proprietary rare disease platform focused on the real-world data repository, which contains over 3.6 billion weighted data points from approximately 595,000 patients from over 120 countries.


The company's platform contains epidemiologic, phenotypic, and genetic data representing the worldwide population and a biobank of these patients' blood samples. CENTOGENE acknowledges that this is the only platform that analyses multi-level data comprehensively to enhance the understanding of rare genetic disorders, which will help to identify patients and improve the pharmaceutical partners' potential to bring orphan drugs to market. The company partnered with over 40 pharmaceutical partners representing over 45 rare diseases as of September 30, 2020.


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/centogene-extends-collaboration-with-takeda-nwid-345.html